Volinanserin
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (R)-(2,3-dimetoksifenil)-[1-[2-(4-fluorofenil)etil]-4-piperidil]metanol | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 139290-65-6 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 5311271 | ||
| ChemSpider[3] | 4470782 | ||
| UNII | EW71EE171J 
| ||
| ChEMBL[4] | CHEMBL74355 | ||
| Hemijski podaci | |||
| Formula | C22H28FNO3 | ||
| Mol. masa | 373,46 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Volinanserin (MDL-100,907) je visoko selektivan antagonist 5-HT2A receptor. On je u širokoj upotrebi u naučnim istraživanjima za istraživanje funkcije 5-HT2A receptora.[5][6][7] Volinanserin se isto tako ispituje kao potencijalni antipsihotik, antidepresiv i tretman za insomniju.[8][9][10]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (November 1992). „5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine”. European Journal of Pharmacology 223 (1): 65–74. DOI:10.1016/0014-2999(92)90819-P. PMID 1362159.
- ↑ Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Rösch F (April 2009). „Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET”. Bioorganic & Medicinal Chemistry 17 (8): 2989–3002. DOI:10.1016/j.bmc.2009.03.021. PMID 19329329.
- ↑ Nic Dhonnchadha BA, Fox RG, Stutz SJ, Rice KC, Cunningham KA (April 2009). „Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model”. Behavioral Neuroscience 123 (2): 382–96. DOI:10.1037/a0014592. PMID 19331461.
- ↑ Offord SJ, Wong DF, Nyberg S (August 1999). „The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action”. Journal of Clinical Pharmacology Suppl: 17S–24S. PMID 10434243.
- ↑ Marek GJ, Martin-Ruiz R, Abo A, Artigas F (December 2005). „The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine”. Neuropsychopharmacology 30 (12): 2205–15. DOI:10.1038/sj.npp.1300762. PMID 15886717.
- ↑ Teegarden BR, Al Shamma H, Xiong Y (2008). „5-HT(2A) inverse-agonists for the treatment of insomnia”. Current Topics in Medicinal Chemistry 8 (11): 969–76. DOI:10.2174/156802608784936700. PMID 18673166.
